

6.3: Balance sheet for implementing Guideline

	Current no	Unit Cost (\$)	% of patients ¹ ₂	Current cost (x \$1000)	Subtotal (x \$1000)	% of total costs	Projected Numbers	% of patients ¹²	Projected cost (x \$1000)	Sub total (x \$1000)	% of total costs	Differences*
Prevalence of HMB (per annum)	111,000 ¹	-	-				110,000					
Prevalence of women who consult with HMB	66,000 ²	-	-				66,000					
GP visit - initial	66,000	32.00	100	2112			66,000	100	2112			
GP visit - repeat	10,560	32.00	16	347		11%	10,560	16	347			240,000
Specialist consult	9,240	107.00	14	980	3,440		6,640	10	735	3,190	10%	
Full blood count	660,000	10	100	692				100	692			
Transvaginal ultrasound		120	20	1584				25	1980			
Endometrial sampling												
pipelle		120	9.0	713				4.5	356			
hysteroscopy(GA)		800	2.5	1320				0.5	264			
hysteroscopy (outpatient)		300	0.5	99				2.5	495			
lab costs		67		533	4,940	16% ⁹			333	4,120	13%	-820,000
			<u>12</u>					<u>7.5</u>				
Oral contraceptive pill	-	6.46 ³	10	626				10	568			
Progestogens												
long course	-	21.20 ³		-				4	378			
short course	-	3.37 ³	26	900				8	300			
NSAIDs	-	3.13 ³⁴	15	160				15	160			
Danazol	-	39.81 ³		-				-	-			
Tranexamic Acid	-	17.49 ³	5	786				15				
LNG IUS	-	49.00 ⁵	-	-				15	5			
			<u>54⁶</u>		2,690	9% ¹⁰		<u>66⁶</u>		4,520	15%	1,840
Endometrial ablation (public) ⁷	-	1242	0.3	217				0.5	435			
Endometrial ablation (private) ⁸	-	2222	0.3	389				0.5	733			

Hysterectomy (public) ⁷	-	2600	3.7	63%				2.0	3432			
Hysterectomy (pvte) ⁸	-	4000	4.8	12560				2.5	6720			
			9.0	5950	19,562	64% ¹¹		6		\$11,320	41% ¹¹	-6,980
		Total cost (current)			\$30,630				Total projected cost	\$24,420	Total Savings (projected)	-6,210

Footnotes - figures are per annum unless otherwise stated and GST exclusive

- 1 10% of women in the reproductive age group (based on UK figures) (Coulter 1991).
- 2 Estimated that 60% of women with HMB consult GP, and 16% have repeat consultation and 14% specialist referral rate (RNZCGP data).
- 3 Mean cost per cycle, includes dispensing fee and mark up.
- 4 Mean cost per cycle for mefenamic acid, naprosyn, diclofenac.
- 5 Cost does not include repeat consultations.
- 6 Percentage of patients who consult and are prescribed medical therapy.
- 7 Public hospital costs are estimated from annual diagnostic related groups provided by North Health 1997 for uncomplicated surgery and likely to be an underestimate.
- 8 Costs are based on an estimate of the Southern Cross schedule.
- 9 The numbers having diagnostic tests are estimates only as no data available solely for premenopausal women. There may also be some overlap between transvaginal ultrasound and pipelle sampling.
- 10 All percentages for medical therapy are estimates only. Assumes costs for 12 months and does not include the costs of repeat prescriptions.
- 11 Public / private split is an estimate only.
- 12 Percentages are rounded and current cost worked out on actual percentages